Currently Viewing:
Community Oncology Alliance 2017
Dr Barbara McAneny on Leveling the Playing Field for Community Oncology
April 27, 2017
Currently Reading
Congressman, Pharmacist, and Lawyer Debate PBMs, Drug Prices at Annual COA Meeting
April 27, 2017
Oncology Practice Administrators Discuss Early Findings From the OCM
April 27, 2017
Oncologists Believe Achieving Cancer Moonshot Goals Should Start in the Community
April 28, 2017
Christian Downs on the Importance of Developing the Oncology Workforce
April 28, 2017
Dr Basit Chaudhry: Feedback Provides Potential Changes for the OCM
April 28, 2017
Linking Claims, Clinical Data Is Essential for a Learning Health System
April 28, 2017
Leah Ralph on ACCC's Concerns With GOP Healthcare Reform Proposals
April 30, 2017
Big Data Is Advancing Cancer Care, but Interoperability Remains a Challenge
May 03, 2017
Dr Daniel George on the Challenge of Cancer Vaccines
May 04, 2017
Leah Ralph: ACCC Concerned About Potential Impact of MedPAC Proposals
May 28, 2017
Leah Ralph on the Political and Legal Obstacles to 340B Reform
June 20, 2017
Dr Bobby Green Explains How Changing Oncology Landscape Drives Big Data Initiatives
June 23, 2017
Rose Gerber Discusses Cancer Survivorship's Lifelong Side Effects
June 30, 2017
Dr Basit Chaudhry on the Impact of the Oncology Care Model
July 05, 2017
Dr Barbara McAneny Discusses the Continuing Evolution of the COME HOME Model
July 07, 2017
Rose Gerber's Outlook on the Evolution and Goals of COA'S CPAN
July 13, 2017

Congressman, Pharmacist, and Lawyer Debate PBMs, Drug Prices at Annual COA Meeting

Surabhi Dangi-Garimella, PhD
At the 2017 Community Oncology Conference, participants discussed the impact of pharmacy benefit managers (PBMs) on oncology drug prices and patient access to much needed treatments.
With drug price debates escalating daily, stakeholders in healthcare, particularly in cancer care, have been very vocal about who should take the blame and bring about changes to reduce the cost of care for patients. A white paper commissioned by the Community Oncology Alliance has aimed the spotlight on practices by pharmacy benefit managers (PBMs) that prevent a reduction in drug prices.

At the 2017 Community Oncology Conference, being held April 26-27 at the Gaylord National Hotel and Convention Center in National Harbor, Maryland, panelists discussed the evolution of PBMs, how their role has changed over the years, and the resulting impact on drug prices and patient access.

Participating in the discussion were the Honorable Earl L. “Buddy” Carter, US House of Representatives; Steven D’Amato, BS Pharm, executive director, New England Cancer Specialists; Jonathan E. Levitt, Esq, founding partner, Frier Levitt. Frier Levitt helped develop the COA white paper on PBMs. Joshua Cox, PharmD, BCPS, director of pharmacy, Dayton Physicians Network moderated the discussion.

Cox provided a historic perspective to how PBMs came to be. “In the early '60s, PBMs played a very important role in the drug distribution network—they brought in technology that impacted the drug supply chain,” he said. Over time, however, with consolidations, their patient network grew and PBMs played a greater role in negotiations. The Federal Trade Commission realized soon enough the conflict of interests resulting from the ensuing PBM-manufacturer alliance, and it was eventually broken up, Cox said.

Today, through mergers and acquisitions, PBMs are vertically integrated in the healthcare system and every major PBM owns a specialty or mail-order pharmacy, Cox said, asking the panelists to comment on how they see this impact the healthcare system.

“Escalating prices of prescription medications has shone the light on this issue with PBMs,” Carter said. It is the most talked about topic in Congress, where lawmakers are now looking at the escalating costs and the reasons behind it, he explained, adding that “transparency is the key here.” Three PBMs controlling 80% of the market is not competition in any sense, Carter said. “We need to break that.”

He then cited the example of how pharmaceutical manufacturer Mylan, manufacturer of the EpiPen—which is used to treat life-threating allergic reactions—was abusing the system with its EpiPen price increase.

“PBMs are not focused on patient care, and we have access issues that we constantly face in our clinic” D’Amato explained, adding that patient care is affected because the patients are often forced to go through a PBM to get their drug, instead of at the point of care like we provide. “On a weekly basis, my pharmacists come to me with this information,” D’Amato added, saying that PBMs are diverting prescriptions from our clinic for financial gains, which is unethical, he said.

Levitt explained that the PBMs practice of using protected health information for marketing purposes is illegal under HIPAA under many state laws. This “prescription trolling” should not be accepted by clinics, he said. Another question that he raised was “Where do the DIR [direct and indirect remuneration] fees gathered by PBMs go?” The power to take away 60% to 70% profitability of a prescription is the power to exclude a community practice from the Medicare network, Levitt explained. PBMs have also tried to limit network access and pushed network terminations, he added.

Copyright AJMC 2006-2020 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up